Roche's new Erivedge wins nod in U.K.; Teva, Perrigo roll out copy of Merck's Temodar;

@FiercePharma: Still trending: Pharma professionals feeling angst, but see a few rays of hope. Story | Follow @FiercePharma

@EricPFierce: India's Aurobindo puts sterile injectables unit into a subsidiary to unlock value. Wonder if it will shop it next? Story | Follow @EricPFierce

@CarlyHFierce: Sanofi's statement on the latest bribery allegations in China: Statement | Follow @CarlyHFierce

> Roche's ($RHHBY) new skin cancer drug Erivedge won clearance in the U.K., following conditional approval by European regulators last month. Report

> Teva Pharmaceutical Industries ($TEVA) and Perrigo ($PRGO) have teamed up to launch a generic version of Merck's ($MRK) cancer drug Temodar. Report

> Federal officials are probing the use of antipsychotic drugs on children covered by Medicaid, worried that the powerful treatments are prescribed unnecessarily. Report (sub. req.)

> India's Biocon said it has launched a new treatment for psoriasis, priced at about $130 per vial, or 50% less than rival drugs made by Big Pharma. Report

> Indian officials have given drugmakers 30 more days to re-price the drugs newly added to the list of heavily discounted essential medicines. Report

Medical Device News

@FierceMedDev: Kona snags ex-SonoSite exec to helm renal denervation. Article | Follow @FierceMedDev

@DamianFierce: Medtronic is spending $200M on a telehealth outfit with an eye on slashing healthcare costs. News | Follow @DamianFierce

@MichaelGFierce: New antivirus system could protect medical devices from infection. Article | Follow @MichaelGFierce

> Agilent, SomaLogic team up on Dx technology. Item

> Montreal's EMcision launches catheters for pancreatic cancer. More

Biotech News

@FierceBiotech: Icon signs up to boost Taiwan's stake in drug development. FierceCRO article | Release | Follow @FierceBiotech

@JohnCFierce: If Roche does try to buy Alexion, the company is going to get slaughtered by the analysts. More | Follow @JohnCFierce

@RyanMFierce: CollabRx elbows into software game for gene interpretation. FierceBiotech IT story | Follow @RyanMFierce

@EmilyMFierce: Newly discovered proteins could play role in destroying cancer cells. More from FierceBiotech Research | Follow @EmilyMFierce

> Biotechs crowd list of top growth leaders as Big Pharmas shrink staffs. Feature

> Which are the most efficient drug developers in biopharma? More

> Vical discards melanoma immunotherapy Allovectin after PhIII failure. Report

CRO News

> Covance offers service to keep contracts under control. Item

> ScinoPharm, Sundia team up in China. Report

> Parexel bets big on the future as revenue swells. Story

> AMRI swings to red despite another sales jump. More

> InVentiv takes aim at blockbusters with biosimilar deal. Article

Biotech IT News

> Medidata to score $287.5M in major financing. News

> CollabRx elbows into software game for gene interpretation. More

> Roche rolls out updated software for next-generation sequencing. Report

> Big Data analysis outfit GNS teams with Inova on predicting preterm birth. Story

> Gene by Gene acquires software upstart Arpeggi. Article

And Finally... New muscle-building drugs in development could be the next big thing in sports doping, experts say. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.